(2023). Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification. Diabet Med, e15200. http://doi.org/10.1111/dme.15200.
(2022). Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort. Clin Kidney J, 15, 2124-2134. http://doi.org/10.1093/ckj/sfac168.
(2022). Glycaemic variability and progression of chronic kidney disease in people with diabetes and comorbid kidney disease: Retrospective cohort study. Diabetes Res Clin Pract, 193, 110117. http://doi.org/10.1016/j.diabres.2022.110117.
(2022). Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility. Kidney Int Rep, 7, 2059-2070. http://doi.org/10.1016/j.ekir.2022.05.033.
(2019). Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus. Am J Nephrol. http://doi.org/10.1159/000504558.